Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. Beacon Therapeutics is a blend of three startup company dedicated to gene therapy studies for the eye – Nightstar Therapeutics, Gyroscope Therapeutics, and Applied Genetic Technologies Corp (AGTC), which are all owned by parent company, Syncona Limited.  Beacon Therapeutics now occupies 50% of Building 1 in Foundation Park, at the Progress District in Alachua, Florida. Concept Companies recently completed the development of their 21,445 sf office and laboratory space adjacent to Building 1, which they will solely occupy.